Usefulness of Biomarkers in the Diagnosis and Prognosis of Early-Onset Cognitive Impairment
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Early-onset cognitive impairment diagnosis is often challenging due to the overlapping symptoms between the different degenerative and non-degenerative conditions. We aimed to evaluate the usefulness of cerebrospinal fluid (CSF) biomarkers in early-onset cognitive impairment differential diagnosis, to assess their contribution to the diagnosis of Alzheimer's disease (AD) based on the new National Institute of Aging-Alzheimer's Association (NIA-AA) workgroup's recommendations and their capacity to predict subsequent decline in early-onset mild cognitive impairment (MCI). 37 controls and 120 patients (clinical onset <65 years) with diagnosis based on criteria available in 2009 (51 MCI, 42 AD, 10 frontotemporal dementia (FTD), 3 posterior cortical atrophy, and 14 primary progressive aphasia (PPA)) were included. In addition, all subjects were also reclassified according to the revised criteria for MCI, AD, FTD, and PPA, excluding CSF data. We assessed the impact of adding the CSF data to the subject categorization according to the NIA-AA criteria. After inclusion of CSF results, 90% of amnestic and 82% of the non-amnestic AD presentation could be categorized as “high probability”, while 3% of AD patients fit into the category “dementia probably not due to AD”. All the 24 MCI patients who progressed to AD dementia and only 1/27 stable MCI presented pathological CSF at baseline. Only 4% of the FTD clinical diagnosis had pathological CSF levels. CSF biomarkers provide high diagnostic accuracy in a clinical context in differentiating AD, frontotemporal lobar degeneration, and controls in presenile subjects and can be used equally in amnestic and non-amnestic AD. Abnormal CSF-AD biomarker levels predict subsequent progression to AD dementia in subjects with early-onset MCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992 · cited 1×
“Previous papers suggest that it is early-onset dementia subjects that could potentially benefit most from the use of CSF biomarkers, because of the lower frequency of pathological CSF in younger control subjects with respect to older control groups [26, 30, 31] and lower frequency of mixed pathological findings postmo…”
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 2×
“Clinicopathological studies have shown that the sensitivity and specificity of the classical clinical criteria for AD diagnosis are around 85% and 70%, respectively [16].”
Age, Neuropathology, and Dementia
Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., & Brayne, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806142 · Cited by 900
Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Buchhave, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.155 · Cited by 664
Focal cortical presentations of Alzheimer's disease
Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581 · cited 2×
“The atypical clinical features of EOAD frequently overlap with those seen in frontotemporal lobar degeneration (FTLD) or non-degenerative disorders such as psychiatric conditions leading to frequent misdiagnosis [6–9].”
Does corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394
Combined CSF tau, p-tau181 and amyloid-β 38/40/42 for diagnosing Alzheimer’s disease
Welge, V., Fiege, O., Lewczuk, P., Mollenhauer, B., Esselmann, H., Klafki, H.-W., Wolf, S., Trenkwalder, C., Otto, M., Kornhuber, J., et al. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-008-0177-6 · Cited by 152
Cited by
Falgàs, N., Sánchez-Valle, R., Bargalló, N., Balasa, M., Fernández-Villullas, G., Bosch, B., Olives, J., Tort-Merino, A., Antonell, A., Muñoz-García, C., et al. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101927 · Cited by 47
“The CSF cut-off values determined by our laboratory were used to classify subjects according to NIA-AA criteria (Balasa et al., 2014).”
MethodSelf-citationBalasa, M., Gelpi, E., Martín, I., Antonell, A., Rey, M. J., Grau‐Rivera, O., Molinuevo, J. L., Sánchez‐Valle, R., Lladó, A., & Catalan collaborative Study Group for FTLD (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12194 · Cited by 32
Self-citationAPP‐derived peptides reflect neurodegeneration in frontotemporal dementia
Illán‐Gala, I., Pegueroles, J., Montal, V., Alcolea, D., Vilaplana, E., Bejanin, A., Borrego‐Écija, S., Sampedro, F., Subirana, A., Sánchez‐Saudinós, M., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50948 · Cited by 20
“Correlation between Ab(1-42), Ab(1-40), and Ab(1-38) and sAPPb in (A) AD group, (B) FTLD-related syndromes group, and (C) healthy control”
BackgroundSelf-citation
Metadata
- Authors
- Balasa, M., Sánchez-Valle, R., Antonell, A., Bosch, B., Olives, J., Rami, L., Castellví, M., Molinuevo, J. L., & Lladó, A.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2014-05-19
- Volume
- 40
- Issue
- 4
- Pages
- 919-927
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1626695651
- Cited by
- 38
- References
- 10
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.